Vasodilators in the treatment of acute heart failure: What we know, what we don't

Heart Failure Reviews

Volumn 14, Issue 4, 2009, Pages 299-307

  Metra, Marco ^a   Teerlink, John R ^b   Voors, Adriaan A ^c   Felker, G Michael ^d   Milo Cotter, Olga ^e   Weatherley, Beth ^e   Dittrich, Howard ^f   Cotter, Gad ^e  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e Momentum Research Inc   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute heart failure; Nitrates; Vasodilators

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; ATRIAL NATRIURETIC FACTOR; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CHIMERIC PROTEIN; DARUSENTAN; DOBUTAMINE; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; ENOXIMONE; FUROSEMIDE; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; MORPHINE; NATRIURETIC FACTOR; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; PLACEBO; RELAXIN; ROLOFYLLINE; SITAXSENTAN; TEZOSENTAN; UNINDEXED DRUG; URODILATIN; VASODILATOR AGENT;

ACUTE HEART FAILURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG INDICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FILLING PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PERFORMANCE; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; LOW DRUG DOSE; MORTALITY; MYOCARDIAL DISEASE; NONHUMAN; OPTIMAL DRUG DOSE; ORGAN BLOOD FLOW; PATHOPHYSIOLOGY; PATIENT MONITORING; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SYMPTOM; SYSTOLIC DYSFUNCTION; VASOCONSTRICTION;

ACUTE DISEASE; ATRIAL NATRIURETIC FACTOR; BENZOIC ACIDS; ELAPID VENOMS; ENDOTHELIN-1; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NITRATES; PEPTIDE FRAGMENTS; PROGNOSIS; PYRIDINES; RECEPTORS, ENDOTHELIN; RELAXIN; TETRAZOLES; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 70449528751     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9127-5     Document Type: Review

References (60)

1. MR Constanzo RS Johannes M Pine, et al. 2007 The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database Am Heart J 154 267 277 10.1016/j.ahj.2007.04.033 10.1016/j.ahj.2007.04.033 (Pubitemid 47071897)
2. MS Nieminen M Bohm MR Cowie, et al. 2005 Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology Eur Heart J 26 384 416 10.1093/eurheartj/ehi044 10.1093/eurheartj/ehi044 15681577 (Pubitemid 40283098)
3. K Dickstein A Cohen-Solal G Filippatos, et al. 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 10 933 989 10.1016/j.ejheart. 2008.08.005 18826876
4. M Gheorghiade F Zannad G Sopko, et al. 2005 Acute heart failure syndromes: current state and framework for future research Circulation 112 3958 3968 10.1161/CIRCULATIONAHA.105.590091 10.1161/CIRCULATIONAHA.105.590091 16365214 (Pubitemid 43739494)
5. M Gheorghiade W Abraham N Albert, et al. 2006 Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure J Am Med Assoc 296 2217 2226 10.1001/jama.296.18.2217 10.1001/jama.296.18.2217 (Pubitemid 44708052)
6. G Filippatos F Zannad 2007 An introduction to acute heart failure syndromes: definition and classification Heart Fail Rev 12 87 90 10.1007/s10741-007-9008-3 10.1007/s10741-007-9008-3 17508282 (Pubitemid 46916952)
7. Teerlink JR (2008) Diagnosis and management of acute heart failure. In: Libby P, Bonow RO, Mann DL, Zipes DP (eds) Braunwald's heart disease, vol 8. Philadelphia, Elsevier, pp 583-610
8. Heart Failure Society of America 2006 Executive summary: HFSA 2006 comprehensive heart failure practice guideline J Card Fail 12 10 38 10.1016/j.cardfail.2005.12.001 10.1016/j.cardfail.2005.12.001 (Pubitemid 43267749)
9. G Cotter M Metra O Milo-Cotter HC Dittrich M Gheorghiade 2008 Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation Eur J Heart Fail 10 165 169 10.1016/j.ejheart.2008.01.007 10.1016/j.ejheart.2008.01.007 18279771 (Pubitemid 351222743)
10. G Cotter GM Felker KF Adams O Milo-Cotter CM O'Connor 2008 The pathophysiology of acute heart failure-is it all about fluid accumulation? Am Heart J 155 9 18 10.1016/j.ahj.2006.02.038 10.1016/j.ahj.2006.02.038 18082483 (Pubitemid 350234787)
11. KF Adams Jr GC Fonarow CL Emerman, et al. 2005 ADHERE Scientific Advisory Committee and Investigators Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100, 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) Am Heart J 149 209 216 10.1016/j.ahj.2004.08.005 10.1016/j.ahj.2004.08.005 15846257 (Pubitemid 40348525)
12. O Milo-Cotter KF Adams CM O'Connor N Uriel GM Felker B Weatherley Z Vered G Cotter 2007 Acute heart failure associated with high admission blood pressure-a distinct vascular disorder? Eur J Heart Fail 9 178 183 10.1016/j.ejheart.2006.06.004 10.1016/j.ejheart.2006.06.004 16877039 (Pubitemid 46394490)
13. G Cotter Y Moshkovitz E Kaluski O Milo Y Nobikov A Schneeweiss R Krakover Z Vered 2003 The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure Eur J Heart Fail 5 443 451 10.1016/S1388-9842(03)00100-4 10.1016/S1388-9842(03) 00100-4 12921805 (Pubitemid 37021638)
14. SK Gandhi JC Powers AM Nomier, et al. 2001 The pathogenesis of acute pulmonary edema associated with hypertension N Engl J Med 344 17 22 10.1056/NEJM200101043440103 10.1056/NEJM200101043440103 11136955 (Pubitemid 32064840)
15. MJ Lenzen WJ Scholte op Reimer E Boersma PJ Vantrimpont F Follath K Swedberg J Cleland M Komajda 2004 Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey Eur Heart J 25 1214 1220 10.1016/j.ehj.2004.06.006 10.1016/j.ehj.2004.06. 006 15246639 (Pubitemid 38891571)
16. JD Sackner-Bernstein HA Skopicki KD Aaronson 2005 Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 1487 1491 10.1161/01.CIR.0000159340.93220.E4 10.1161/01.CIR.0000159340.93220.E4 15781736 (Pubitemid 40470642)
17. JD Sackner-Bernstein M Kowalski M Fox K Aaronson 2005 Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials J Am Med Assoc 293 1900 1905 10.1001/jama.293.15.1900 10.1001/jama.293.15.1900 (Pubitemid 40548187)
18. CW Yancy MT Saltzberg RL Berkowitz, et al. 2004 Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial) Am J Cardiol 94 595 601 10.1016/j.amjcard.2004.05.022 10.1016/j.amjcard.2004.05.022 15342289 (Pubitemid 39165837)
19. RM Mentzer Jr MC Oz RN Sladen AH Graeve RF Hebeler Jr JM Luber Jr NG Smedira NAPA Investigators 2007 Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial J Am Coll Cardiol 49 716 726 10.1016/j.jacc.2006.10.048 10.1016/j.jacc.2006.10.048 17291938 (Pubitemid 46205038)
20. M Metra S Nodari G Parrinello, et al. 2007 The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T Eur J Heart Fail 9 776 786 10.1016/j.ejheart. 2007.05.007 10.1016/j.ejheart.2007.05.007 17573240 (Pubitemid 47212835)
21. JN Cohn JA Franciosa GS Francis, et al. 1982 Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study N Engl J Med 306 1129 1135 7040956
22. U Elkayam G Tasissa C Binanay, et al. 2007 Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure Am Heart J 153 98 104 10.1016/j.ahj.2006.09.005 10.1016/j.ahj.2006.09.005 17174645 (Pubitemid 44880871)
23. A Mebazaa MS Nieminen M Packer, et al. 2007 Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial J Am Med Assoc 297 1883 1891 10.1001/jama.297.17.1883 10.1001/jama.297.17. 1883 (Pubitemid 46707842)
24. GS Francis MT Olivari SR Goldsmith TB Levine G Pierpont JN Cohn 1983 The acute response of plasma norepinephrine, renin activity, and arginine vasopressin to short-term nitroprusside and nitroprusside withdrawal in patients with congestive heart failure Am Heart J 106 1315 1320 10.1016/0002-8703(83) 90039-X 10.1016/0002-8703(83)90039-X 6359844
25. RW Troughton LK Lewis TG Yandle AM Richards MG Nicholls 2000 Hemodynamic, hormone, and urinary effects of adrenomedullin infusion in essential hypertension Hypertension 36 588 593 11040240
26. TD Giles IL Pina AC Quiroz, et al. 1992 Hemodynamic and neurohormonal responses to intravenous Nicorandil in congestive heart failure in humans J Cardiovasc Pharmacol 20 572 578 10.1097/00005344-199210000-00010 10.1097/00005344-199210000-00010 1280713
27. Publication Committee for the VMAC [Vasodilatation in the Management of Acute CHF] Investigators 2002 Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial JAMA 287 1531 1540 10.1001/jama.287.12.1531
28. G Cotter E Metzkor E Kaluski, et al. 1998 Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema Lancet 351 389 393 10.1016/S0140-6736(97)08417-1 10.1016/S0140-6736(97)08417-1 9482291 (Pubitemid 28064161)
29. A Sharon I Shpirer E Kaluski, et al. 2000 High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema J Am Coll Cardiol 36 832 837 10.1016/S0735-1097(00)00785-3 10.1016/S0735-1097(00)00785-3 10987607 (Pubitemid 30681606)
30. U Elkayam F Bitar MW Akhter S Khan S Patrus M Derakhshani 2004 Intravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitations J Cardiovasc Pharm Ther 9 227 241 10.1177/107424840400900403 10.1177/107424840400900403 (Pubitemid 40130010)
31. M Packer J Meller N Medina R Gorlin MV Herman 1979 Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure N Engl J Med 301 1193 1197 503111 (Pubitemid 10163033)
32. W Mullens Z Abrahams GS Francis HN Skouri RC Starling JB Young DO Taylor WH Tang 2008 Sodium nitroprusside for advanced low-output heart failure J Am Coll Cardiol 52 200 207 10.1016/j.jacc.2008.02.083 10.1016/j.jacc.2008.02.083 18617068 (Pubitemid 351915785)
33. WS Colucci U Elkayam DP Horton, et al. 2000 Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure N Engl J Med 343 246 253 10.1056/NEJM200007273430403 10.1056/NEJM200007273430403 10911006 (Pubitemid 30490392)
34. RM Mills TH LeJemtel DP Horton, et al. 1999 Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial J Am Coll Cardiol 34 155 162 10.1016/S0735-1097(99)00184-9 10.1016/S0735-1097(99)00184-9 10400005
35. M Yanagisawa H Kurihara Y Kimura, et al. 1988 A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 332 411 415 10.1038/332411a0 10.1038/332411a0 2451132 (Pubitemid 18090241)
36. JR Teerlink 2002 The role of endothelin in the pathogenesis of heart failure Curr Cardiol Rep 4 206 212 10.1007/s11886-002-0052-2 10.1007/s11886-002-0052-2 11960589
37. MP Love JJV McMurray 1996 Endothelin in chronic heart failure: current position and future prospects Cardiovasc Res 31 665 674 8763394
38. D Aronson AJ Burger 2003 Neurohormonal prediction of mortality following admission for decompensated heart failure Am J Cardiol 91 245 248 10.1016/S0002-9149(02)03119-3 10.1016/S0002-9149(02)03119-3 12521645 (Pubitemid 36084315)
39. JR Teerlink BM Massie JGF Cleland D Tzivoni for the RITZ-1 Investigators 2001 A double-blind, parallel-group, multi-center, placebocontrolled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure Circulation 104 II 526 abstract
40. G Torre-Amione JB Young WS Colucci, et al. 2003 Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 42 140 147 10.1016/S0735-1097(03)00556-4 10.1016/S0735-1097(03)00556-4 12849674 (Pubitemid 36760775)
41. CM O'Connor WA Gattis KF Adams Jr, et al. 2003 Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4) J Am Coll Cardiol 41 1452 1457 10.1016/S0735-1097(03)00194-3 10.1016/S0735-1097(03)00194-3 12742280 (Pubitemid 36543358)
42. E Kaluski I Kobrin R Zimlichman, et al. 2003 RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, doubleblind, placebo-controlled study J Am Coll Cardiol 41 204 210 10.1016/S0735-1097(02)02708-0 10.1016/S0735-1097(02)02708-0 12535809 (Pubitemid 36092185)
43. JR Teerlink JJ McMurray RC Bourge, et al. 2005 Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS) Am Heart J 150 46 53 10.1016/j.ahj.2005.04.035 10.1016/j.ahj.2005.04.035 16084150 (Pubitemid 41097429)
44. JJ McMurray JR Teerlink G Cotter, et al. 2007 Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials J Am Med Assoc 298 2009 2019 10.1001/jama.298.17. 2009 10.1001/jama.298.17.2009 (Pubitemid 350074798)
45. W Forssmann M Meyer K Forssmann 2001 The renal urodilatin system: clinical implications Cardiovasc Res 51 450 462 10.1016/S0008-6363(01)00331-5 10.1016/S0008-6363(01)00331-5 11476735 (Pubitemid 32718593)
46. V Mitrovic H Luss K Nitsche, et al. 2005 Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial Am Heart J 150 1239.e1-8 10.1016/j.ahj.2005.01.022 (Pubitemid 41773529)
47. V Mitrovic PM Seferovic D Simeunovic, et al. 2006 Haemodynamic and clinical effects of ularitide in decompensated heart failure Eur Heart J 27 2823 2832 10.1093/eurheartj/ehl337 10.1093/eurheartj/ehl337 17074775 (Pubitemid 44871466)
48. H Lüss V Mitrovic PM Seferovic, et al. 2008 Renal effects of ularitide in patients with decompensated heart failure Am Heart J 155 1012.e1-8 10.1016/j.ahj.2008.02.011 18513512 (Pubitemid 351721023)
49. O Lisy BK Huntley DJ McCormick PA Kurlansky JC Burnett Jr 2008 Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP J Am Coll Cardiol 52 60 68 10.1016/j.jacc.2008.02.077 10.1016/j.jacc.2008.02.077 18582636 (Pubitemid 351852935)
50. J Novak LJ Parry JE Matthews, et al. 2006 Evidence for local relaxin ligand-receptor expression and function in arteries FASEB J 20 2352 2362 10.1096/fj.06-6263com 10.1096/fj.06-6263com 17077312 (Pubitemid 44953865)
51. T Bani-Sacchi M Bigazzi D Bani PF Mannaioni E Masini 1995 Relaxin-induced increased coronary flow through stimulation of nitric oxide production Br J Pharmacol 116 1589 1594 8564223
52. LA Danielson OD Sherwood KP Conrad 1999 Relaxin is a potent renal vasodilator in conscious rats J Clin Invest 103 525 533 10.1172/JCI5630 10.1172/JCI5630 10021461
53. M Toth P Taskinen H Ruskoaho 1996 Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart J Endocrinol 150 487 495 10.1677/joe.0.1500487 10.1677/joe.0.1500487 8882168
54. EN Unemori ME Erikson SE Rocco KM Sutherland DA Parsell J Mak BH Grove 1999 Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women Human Reprod (Oxford, England) 14 800 806 10.1093/humrep/14.3.800 10.1093/humrep/14.3.800
55. G Boerrigter LC Costello-Boerrigter A Cataliotti H Lapp JP Stasch JC Burnett Jr 2007 Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure Hypertension 49 1128 1133 10.1161/HYPERTENSIONAHA. 106.083832 10.1161/HYPERTENSIONAHA.106.083832 17325237 (Pubitemid 351664312)
56. V Mitrovic H Lapp N Franz, et al. 2008 The soluble guanilate cyclase activator BAY 58-2667 has a favourable safety profile and improbe cardiopulmonary hemodynamics in acute decompensated heart failure Eur J Heart Fail 7 Suppl 1 1 abstract
57. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy Circulation 105 1348 1353 10.1161/hc1102.105264 10.1161/hc1102.105264 11901047 (Pubitemid 34260427)
58. 1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment J Card Fail 13 609 617 10.1016/j.cardfail.2007.08.006 10.1016/j.cardfail.2007.08.006 17923351 (Pubitemid 47513547)
59. 1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance J Am Coll Cardiol 50 1551 1560 10.1016/j.jacc.2007.07.019 10.1016/j.jacc.2007.07.019 17936154 (Pubitemid 47532320)
60. G Cotter HC Dittrich B Davison Weatherley DM Bloomfield CM O'Connor M Metra BM Massie Protect Steering Committee, Investigators and Coordinators 2008 The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A(1) receptor antagonist rolofylline in patients with acute heart failure and renal impairment J Card Fail 14 631 640 10.1016/j.cardfail.2008.08. 010 10.1016/j.cardfail.2008.08.010 18926433